Drug company executives sacked after allegations of illegal surveillance
BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7392.730/d (Published 05 April 2003) Cite this as: BMJ 2003;326:730- Carl Kovac
- Budapest
Two executives at Lilly Hungaria, the Hungarian subsidiary of US pharmaceutical giant Eli Lilly, have been dismissed after allegations that they ordered the illegal surveillance of officials of the National Health Fund, the body that manages the government budget for health care. The officials have the power to influence decisions on state drug subsidies.
The company's membership of the Association of Innovative Drug Producers has been suspended. The association has issued a statement saying that “Lilly Hungaria has admitted to making a mistake and claims they are taking the necessary steps to investigate the case within the company.”
The alleged …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.